DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Sep 30, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.